专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO9852582A8 NON-MYELOABLATIVE TOLEROGENIC TREATMENT 审中-公开
标题翻译：非骨髓增生性全身性治疗
公开(公告)号：WO9852582A8
公开(公告)日：1999-04-15
申请号：PCT/US9810575
申请日：1998-05-22
申请人： HADASIT MED RES SERVICE , BAXTER INT , SLAVIN SHIMON , PRIGOZHINA TATYANA
发明人： SLAVIN SHIMON , PRIGOZHINA TATYANA
IPC分类号： A01K67/027 , A61K35/12 , A61K35/18 , A61K35/28 , A61K39/00 , A61K45/00 , A61P37/06 , C12N5/06 , A61K35/14 , A61K47/48
CPC分类号： A61K35/28 , A01K67/0271 , A61K31/675 , A61K35/12 , A61K35/17 , A61K39/001 , A61K2035/122 , A61K2039/5158
摘要： The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal.
摘要翻译：本发明的特征在于在宿主中诱导供体特异性耐受的方法。本发明的耐受性治疗可以在移植供体来源的材料之前施用于宿主。致耐受性治疗包括（1）以足以降低但不一定消除宿主哺乳动物的功能性T淋巴细胞群体的非清髓性方案向宿主哺乳动物施用免疫抑制剂; （2）将来自非同基因供体的供体抗原注入宿主哺乳动物; （3）使用非清髓性剂量的淋巴细胞毒性剂或耐受剂，消除对注入的供体抗原起反应的那些宿主T淋巴细胞; 和（4）向宿主哺乳动物施用供体造血细胞。

2. 发明申请

WO2002070023A3 COMPOSITIONS COMPRISING BONE MARROW CELLS TOGETHER WITH DEMINERALIZED AND/OR MINERALIZED BONE MATRIX AND USES THEREOF IN THE INDUCTION OF BONE AND CARTILAGE FORMATION 审中-公开
公开(公告)号：WO2002070023A3
公开(公告)日：2002-09-12
申请号：PCT/IL2002/000172
申请日：2002-03-05
申请人： HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. , SLAVIN, Shimon , GUREVITCH, Olga , KURKALLI, Basan, Gowda, S. , PRIGOZHINA, Tatyana
发明人： SLAVIN, Shimon , GUREVITCH, Olga , KURKALLI, Basan, Gowda, S. , PRIGOZHINA, Tatyana
IPC分类号： A61K35/32
摘要： A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM) and optionally comprising bone morphogenetic protein/s (BMP) and/or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint and/or a cranio-facial-maxillary bone, for restoring and/or enhancing the formation of a new hyaline cartilage and subchondral bone structure. The composition of the invention and method of treatment employing the same may be used for the treatment of hereditary or acquired bone disorders, hereditary or acquired cartilage disorders, malignant bone or cartilage disorders, metabolic bone diseases, bone infections, conditions involving bone or cartilage deformities and Paget's disease. The composition and method may further be used for the correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery, for support of implants of joints, cranio-facial-maxillary bones, or other musculoskeletal implants, including artificial implants. The method of the invention may further be used for treating damaged joints or degenerative arthropathy associated with malformation and/or dysfunction of cartilage and/or subchondral bone. A kit is provided for performing transplantation into a joint or a cranio-facial-maxillary bone of a mammal of the composition of the invention.

3. 发明申请

WO2002069988A3 COMPOSITIONS COMPRISING BONE MARROW CELLS TOGETHER WITH DEMINERALIZED AND/OR MINERALIZED BONE MATRIX AND THEIR USE IN BONE MARROW TRANSPLANTATION 审中-公开
公开(公告)号：WO2002069988A3
公开(公告)日：2002-09-12
申请号：PCT/IL2002/000171
申请日：2002-03-05
申请人： SLAVIN, Shimon , GUREVITCH, Olga , KURKALLI, Basan Gowda S. , PRIGOZHINA, Tatyana
发明人： SLAVIN, Shimon , GUREVITCH, Olga , KURKALLI, Basan Gowda S. , PRIGOZHINA, Tatyana
IPC分类号： A61K35/32
摘要： A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoietic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerance, for the prevention of graft-v.-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.

4. 发明申请

WO2002070023A2 COMPOSITIONS COMPRISING BONE MARROW CELLS TOGETHER WITH DEMINERALIZED AND/OR MINERALIZED BONE MATRIX AND USES THEREOF IN THE INDUCTION OF BONE AND CARTILAGE FORMATION 审中-公开
标题翻译：包含骨髓基质细胞与成骨细胞和/或矿化骨骼基质的组合物及其在诱导骨骼和骨髓形成中的用途
公开(公告)号：WO2002070023A2
公开(公告)日：2002-09-12
申请号：PCT/IL2002/000172
申请日：2002-03-05
申请人： HADASIT MEDICAL RESEARCH SERVICES & DEVELOPMENT LTD. , SLAVIN, Shimon , GUREVITCH, Olga , KURKALLI, Basan, Gowda, S. , PRIGOZHINA, Tatyana
发明人： SLAVIN, Shimon , GUREVITCH, Olga , KURKALLI, Basan, Gowda, S. , PRIGOZHINA, Tatyana
IPC分类号： A61L
CPC分类号： A61K35/32 , A61K35/28 , A61K38/1875 , A61K2300/00
摘要： A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM) and optionally comprising bone morphogenetic protein/s (BMP) and/or other active agents, particularly for use in the transplantation of mesenchymal progenitor cells into a joint and/or a cranio-facial-maxillary bone, for restoring and/or enhancing the formation of a new hyaline cartilage and subchondral bone structure. The composition of the invention and method of treatment employing the same may be used for the treatment of hereditary or acquired bone disorders, hereditary or acquired cartilage disorders, malignant bone or cartilage disorders, metabolic bone diseases, bone infections, conditions involving bone or cartilage deformities and Paget's disease. The composition and method may further be used for the correction of complex fractures, bone replacement and formation of new bone in plastic or sexual surgery, for support of implants of joints, cranio-facial-maxillary bones, or other musculoskeletal implants, including artificial implants. The method of the invention may further be used for treating damaged joints or degenerative arthropathy associated with malformation and/or dysfunction of cartilage and/or subchondral bone. A kit is provided for performing transplantation into a joint or a cranio-facial-maxillary bone of a mammal of the composition of the invention.
摘要翻译：包含骨髓细胞（BMC）和去矿化骨基质（DBM）和/或矿化骨基质（MBM）和任选地包含骨形态发生蛋白（BMP）和/或其他活性剂的组合物，特别是用于移植间充质祖细胞进入关节和/或头颅面上颌骨，用于恢复和/或增强新型透明软骨和软骨下骨结构的形成。本发明的组合物及其使用方法可用于治疗遗传性或获得性骨病，遗传性或获得性软骨疾病，恶性骨或软骨疾病，代谢性骨病，骨感染，涉及骨或软骨畸形的病症和佩吉特病。组合物和方法还可用于矫正复合骨折，骨替代和塑性或性手术中新骨形成，以支持关节植入物，颅面上颌骨或其他肌骨骼植入物，包括人造植入物。本发明的方法还可用于治疗与软骨和/或软骨下骨的畸形和/或功能障碍相关的损伤关节或退行性关节病。提供用于进行移植到本发明组合物的哺乳动物的关节或头颅面上颌骨中的试剂盒。

5. 发明申请

WO02069988A2 COMPOSITIONS COMPRISING BONE MARROW CELLS TOGETHER WITH DEMINERALIZED AND/OR MINERALIZED BONE MATRIX AND THEIR USE IN BONE MARROW TRANSPLANTATION 审中-公开
标题翻译：包含骨髓基质细胞与成骨细胞和/或矿化骨基质的组合物及其在骨髓移植中的用途
公开(公告)号：WO02069988A2
公开(公告)日：2002-09-12
申请号：PCT/IL0200171
申请日：2002-03-05
申请人： HADASIT MED RES SERVICE , SLAVIN SHIMON , GUREVITCH OLGA , KURKALLI BASAN GOWDA S , PRIGOZHINA TATYANA
发明人： SLAVIN SHIMON , GUREVITCH OLGA , KURKALLI BASAN GOWDA S , PRIGOZHINA TATYANA
IPC分类号： A61K38/22 , A61K35/12 , A61K35/28 , A61K35/32 , A61K38/18 , A61P7/06 , A61P19/02 , A61P19/08 , A61P35/00 , C12N5/08 , A61K35/00
CPC分类号： A61K35/32 , A61K35/28 , A61K38/1875 , A61K2300/00
摘要： A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoietic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerance, for the prevention of graft-v.-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.
摘要翻译：包含骨髓细胞（BMC）和去矿物质骨基质（DBM）和/或矿化骨基质（MBM）的组合物，任选地包括骨形态发生蛋白（BMP），特别是用于骨髓移植，进入骨髓腔或骨骼外位点及其移植/植入方法。本发明的组合物和方法能够恢复和/或增强源自移植的BMC的造血微环境的形成，并且可用于治疗造血障碍，例如干细胞和/或其产物的缺乏，导致异常干细胞和/或产物，或恶性或非恶性起源的造血障碍。本发明的组合物和方法也可用于诱导移植物耐受性，以防止移植物宿主病。最重要的是，本发明的组合物和方法可以用于治疗主要或二次影响支持和调节造血的基质微环境的疾病。还提供了用于与DBM和/或MBM混合的用于移植到BMC的哺乳动物中的试剂盒。

6. 发明申请

WO9852582A9 NON-MYELOABLATIVE TOLEROGENIC TREATMENT 审中-公开
公开(公告)号：WO9852582A9
公开(公告)日：1999-05-14
申请号：PCT/US9810575
申请日：1998-05-22
申请人： HADASIT MED RES SERVICE , BAXTER INT , SLAVIN SHIMON , PRIGOZHINA TATYANA
发明人： SLAVIN SHIMON , PRIGOZHINA TATYANA
IPC分类号： A01K67/027 , A61K35/12 , A61K35/18 , A61K35/28 , A61K39/00 , A61K45/00 , A61P37/06 , C12N5/06 , A61K35/14 , A61K47/48
CPC分类号： A61K35/28 , A01K67/0271 , A61K31/675 , A61K35/12 , A61K35/17 , A61K39/001 , A61K2035/122 , A61K2039/5158
摘要： The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal.

7. 发明申请

WO9852582A2 NON-MYELOABLATIVE TOLEROGENIC TREATMENT 审中-公开
标题翻译：非骨髓增生性治疗
公开(公告)号：WO9852582A2
公开(公告)日：1998-11-26
申请号：PCT/US9810575
申请日：1998-05-22
申请人： HADASIT MED RES SERVICE , BAXTER INT , SLAVIN SHIMON , PRIGOZHINA TATYANA
发明人： SLAVIN SHIMON , PRIGOZHINA TATYANA
IPC分类号： A01K67/027 , A61K35/12 , A61K35/18 , A61K35/28 , A61K39/00 , A61K45/00 , A61P37/06 , C12N5/06 , A61K35/00
CPC分类号： A61K35/28 , A01K67/0271 , A61K31/675 , A61K35/12 , A61K35/17 , A61K39/001 , A61K2035/122 , A61K2039/5158
摘要： The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional T lymphocyte population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host T lymphocytes responding to the infused donor antigens using a non-myeloablative dose of lymphocytotoxic or tolerizing agent; and (4) administering donor hematopoietic cells to the host mammal.
摘要翻译：本发明的特征在于在宿主中诱导供体特异性耐受的方法。本发明的耐受性治疗可以在移植供体来源的材料之前施用于宿主。耐受性治疗涉及（1）以足以减少但不一定消除宿主哺乳动物功能性T淋巴细胞群体的非骨髓清除方案向宿主哺乳动物施用免疫抑制剂; （2）将来自非同基因供体的供体抗原输入宿主哺乳动物; （3）使用非清髓剂量的淋巴细胞毒性或耐受剂消除对输注的供体抗原的响应的宿主T淋巴细胞; 和（4）向宿主哺乳动物施用供体造血细胞。

8. 发明专利

IL141813A MIXTURE COMPRISING BONE MARROW CELLS TOGETHER WITH DEMINERALIZED AND/OR MINERALIZED BONE MATRIX AND USES THEREOF IN THE PREPARATION OF COMPOSITIONS FOR THE TREATMENT OF HEMATOPOIETIC DUSIRDERS 未知
公开(公告)号：IL141813A
公开(公告)日：2010-04-15
申请号：IL14181301
申请日：2001-03-05
申请人： HADASIT MED RES SERVICE , GUREVITCH OLGA , SLAVIN SHIMON , PRIGOZHINA TATYANA
发明人： GUREVITCH OLGA , SLAVIN SHIMON , PRIGOZHINA TATYANA
IPC分类号： A61K38/22 , A61K35/12 , A61K35/28 , A61K35/32 , A61K38/18 , A61P7/06 , A61P19/02 , A61P19/08 , A61P35/00 , C12N5/08
摘要： A composition comprising bone marrow cells (BMC) and demineralized bone matrix (DBM) and/or mineralized bone matrix (MBM), optionally comprising bone morphogenetic protein (BMP), particularly for use in bone marrow transplantation, into bone marrow cavity or into extraskeletal sites, and methods of transplantation/implantation thereof. The composition and methods of the invention enable restoring and/or enhancing the formation of hematopoiectic microenvironment originating from the transplanted BMC, and are useful in the treatment of hematopoietic disorders, such as deficiency of stem cells and/or their products, genetic conditions resulting in abnormal stem cells and/or products, or hematopoietic disorders of malignant or non-malignant origin. The composition and method of the invention may also be used for the induction of graft tolerence, for the prevention of graft-v-host disease. It is mostly important that the compositions and methods of the invention may be applied for the treatment of diseases affecting primarily or secondarily the stromal microenvironment that supports and regulates hematopoiesis. Further provided is a kit for transplantation into a mammal of BMC in admixture with DBM and/or MBM.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式